BioSyent Named to the Growth List Ranking of Canada’s Fastest-Growing Companies for Eighth Consecutive Year
October 15 2020 - 8:00AM
BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce
that it has been included in the 32nd annual Growth List, the
definitive ranking of Canada’s Fastest-Growing Companies by
Canadian Business and Maclean’s. The Growth List (formerly the
Growth 500) ranks Canadian companies based on five-year revenue
growth. Results of the annual ranking are published in a special
print issue of Canadian Business with Maclean’s magazine and online
at CanadianBusiness.com and GrowthList.ca.
Based on a five-year revenue growth rate of 75%
(2014 - 2019), BioSyent was named as one of Canada’s
Fastest-Growing Companies on the 2020 Growth List. This is the
eighth consecutive year that BioSyent has been included in this
ranking.
“We are proud to be recognized for our top-line
growth among Canada’s Fastest-Growing Companies for the eighth
consecutive year,” commented René Goehrum, President and CEO of
BioSyent. “We are also proud of BioSyent’s track record of
delivering profitability along with this growth, with Q2 2020
marking the 40th consecutive profitable quarter for the
Company.”
For a direct market quote for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical products that have been
successfully developed, are safe and effective, and have a proven
track record of improving the lives of patients. BioSyent supports
the healthcare professionals that treat these patients by marketing
its products through its community, specialty/hospital and
international business units.
As of the date of this press release, the
Company has 12,808,600 shares issued and outstanding.
For further information please
contact:
Mr. René C. GoehrumPresident and CEOBioSyent
Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web:
www.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2023 to Apr 2024